Pneumonia News and Research

Latest Pneumonia News and Research

‘Traffic light’ guide for pediatric bacterial infection needs refining

Study results suggest that a “traffic light” system for categorizing the severity of infections in children fails to detect a substantial number of serious bacterial infections, particularly urinary tract infections.

26 Feb 2013

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

New technology from the University of Maryland (UM) could potentially provide a five-minute diagnostic test and a vaccine for tough-to-treat Staphylococcus aureus infections, including the antibiotic-resistant MRSA, often called a "super bug," says inventor Mark Shirtliff, PhD, an associate professor at the UM School of Dentistry in Baltimore.

26 Feb 2013

Thermo Fisher Scientific launches Brilliance GBS Agar

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Brilliance GBS Agar for the testing of Group B streptococci (GBS) during pregnancy.

From Thermo Fisher Scientific Inc. 26 Feb 2013

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

25 Feb 2013

Scientists uncover atomic structure of dermcidin

An international team of scientists has discovered how an important natural antibiotic called dermcidin, produced by our skin when we sweat, is a highly efficient tool to fight tuberculosis germs and other dangerous bugs.

22 Feb 2013

Sixth death from novel coronavirus recorded in Britain

"A British man infected with a new virus from the same family as SARS has died, health officials said on Tuesday, bringing the worldwide death toll from the previously unknown disease to six," Reuters reports.

21 Feb 2013

Income inequality equals more hospital readmissions

Patients living in areas of uneven wealth-distribution are at an increased risk for hospital readmission, according to US research findings published in the BMJ.

19 Feb 2013

Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

One of the key reasons why children are missed by immunization programs, particularly in developing countries where Médecins Sans Frontières (MSF) works, is that the products that we currently have in their present formulation are not well-suited to the places that have the most un-immunized children. These are the most challenging contexts to work in.

19 Feb 2013

Hospital mortality performance not boosted by readmission failure

Researchers say they have found no evidence of a link between hospital performance as measured by 30-day mortality rates and that by 30-day readmission rates in US hospitals.

14 Feb 2013

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

14 Feb 2013

CA-MRSA on the rise in nursing homes

While most infection control measures are focused on hospitals, a new study points to the need for more targeted interventions to prevent the spread of drug-resistant bugs in nursing homes as community-associated strains of methicillin-resistant Staphylococcus aureus (CA-MRSA) are on the rise in these facilities. The study is published in the March issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

13 Feb 2013

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.

13 Feb 2013

'Urgent need’ for primary care pneumonia diagnosis tools

While family doctors can exclude pneumonia with a high level of accuracy, they can only identify around a third of radiographically confirmed cases, research shows.

11 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

‘Urgent need’ for primary care pneumonia diagnosis tools

While family doctors can exclude pneumonia with a high level of accuracy, they can only identify around a third of radiographically confirmed cases, research shows.

5 Feb 2013

Gum infections may increase risk for community-acquired pneumonia

People with moderate-to-severe periodontitis are at increased risk for community-acquired pneumonia compared with those with healthy gums, show study findings.

4 Feb 2013

Measles: an interview with Dr. Robert Perry, World Health Organization

Measles is a disease marked by fever, rash, and cold symptoms (red eyes, cough, runny nose) that results in a temporary suppression of the immune system and a drop in vitamin A levels.

4 Feb 2013

Certified IPs more likely to perceive evidence behind infection prevention practices

There is general agreement among hospital infection preventionists (IPs) with respect to which practices have weak or strong evidence supporting their use to prevent healthcare-associated infection, according to a new study published in the February issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

4 Feb 2013

CDC: Adult vaccination rates 'unacceptably low'

According to the CDC, a "substantial increase" in immunizations for adults is necessary.

31 Jan 2013

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

28 Jan 2013